Idelalisib (CAL-101, GS-1101)

目录号:S2226

Idelalisib (CAL-101, GS-1101) Chemical Structure

Molecular Weight(MW): 415.42

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。

规格 价格 库存 购买数量  
RMB 1279.19 现货
RMB 972.85 现货
RMB 3867.24 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献38篇:

客户使用该产品的5个实验数据:

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Ppp2r1afl/fl BCR-ABL1 B-ALL cells transduced with 4-OHT-inducible Cre-ERT2 (Cre) or ERT2-vector (EV) were treated with 4-OHT for 3 days and cell lysates were studied by phospho-protein array analysis. Ppp2r1afl/fl BCR-ABL1 ALL cells were transduced with 4-OHT-inducible Cre or EV control and incubated in the presence of the small molecule signaling inhibitor idelalisib (32 μmol/L; C). Percentages of GFP+ cells were measured by flow cytometry at the times indicated following 4-OHT-treatment. Data are shown as mean ± standard deviation (SD) and representative of at least three independent experiments.

    Cell, 2018, 173(2):470-484. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • 293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。
特性 Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。
靶点
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达,EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比,CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞,降低pAktS473, pAktT308, 和下游靶点S6, EC50为0.1到1.0 μM。 [1] CAL-101 作用于CLL细胞,诱导选择性细胞毒性,不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比,CAL-101作用于CLL 细胞优先产生细胞毒性,和LY294002相比,作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞 缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累,在S期下降,说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\EUXNQ NWrFXms5UUN3ME2yNE41KM7:TR?= NVXKVIlZOjV7OUmzOVI>
CLL PBMCs NVv6Zm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;EUXNQ MoLRTWM2OD1{Lkmgcm0> MmHnNlU6OTd{Nke=
U266 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED6eY01OCEQvF2= MXm0PEBp M1i5OFc6NjVnIHnubIljcXSrb36gdoF1\Q>? NXjINWhtOjV|M{mzN|I>
K562 NFHnPIpHfW6ldHnvckBCe3OjeR?= NH3VU5cyKM7:TR?= MX:zJIg> NHzqfolKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= M3rafVI2ODF2N{e1
K562 M{PIT2Z2dmO2aX;uJGF{e2G7 MX[xJO69VQ>? Ml3IN{Bp M{fPXmlvcGmkaYTpc44hd2ZiUEewV|ZMKHCqb4PwbI9zgWyjdHnvci=> MXqyOVAyPDd5NR?=
K562 MVXGeY5kfGmxbjDBd5NigQ>? MkLCNUDPxE1? MWKzJIg> M37MfGlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= MWeyOVAyPDd5NR?=
K562 MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfTNUDPxE1? NVXLSGN1PzJiaB?= M{TZR2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvci=> MYmyOVAyPDd5NR?=
Primary AML cell M{TKbGZ2dmO2aX;uJGF{e2G7 NGXMc|kyKM7:TR?= MoPwN{Bp MYfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? M4HTPFI2ODF2N{e1
Primary AML cell M{\XRmZ2dmO2aX;uJGF{e2G7 MlnTNUDPxE1? NFe4dFk{KGh? MVfJcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:|cHjvdplt[XSrb36= M4LTUVI2ODF2N{e1
Primary AML cell M2rCfWZ2dmO2aX;uJGF{e2G7 NYTjcnFsOSEQvF2= M3\NTlMhcA>? NUj6NZREUW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=> M2TKVFI2ODF2N{e1
Primary AML cell MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUdVEh|ryP Mlf3N{Bp MUHTeZBxemW|c3nvckBw\iC{Ul7BJJN6dnSqZYPpdy=> NFPQZpQzPTBzNEe3OS=>
Microglia MYXGeY5kfGmxbjDBd5NigQ>? MUm1JO69VQ>? M{Hqc|ExKGh? MV\EUXNQ MlTaSIVkemWjc3Wgc4YhXE6IYTDz[YNz\XSrb36g[pJwdSCOUGOtd5RqdXWuYYTl[EAheDFzMN80SFkyOEFxREmxNGEhdWmlcn;ncIli MlzJNlQ3OjV4OES=
Primary CLL cell M37rPWZ2dmO2aX;uJGF{e2G7 NV\HXoxVOSEQvF2= NH;w[JUyPSCvaX6= MoXZSG1UVw>? NYfoXWFRSmyxY3vzJGJEWi2rbnT1Z4VlKEyFUEGgd4VzcW6nLUWgZYN1cX[jdHnvci=> MlfpNlQxODl{M{O=
JEKO-1 Mn3aSpVv[3Srb36gRZN{[Xl? MoPnNUDPxE1? M2i0OFczKGh? MlfHTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJGloVS2|dHnteYxifGWmIFrFT28uOQ>? MYiyN|M1OTV2MR?=
Granta-519 MYfGeY5kfGmxbjDBd5NigQ>? M4SwelEh|ryP NVLCbGszOiCq NWPQU5NsUW6qaXLpeIlwdiCxZjDBb5QpfDNyODmgdIhwe3Cqb4L5cIF1cW:w MUGyN|M1OTV2MR?=
Granta-519 M3P5RWZ2dmO2aX;uJGF{e2G7 MVKxJO69VQ>? MX2yJIg> NV7xe41WUW6qaXLpeIlwdiCxZjDBb5QpezR5MzmgdIhwe3Cqb4L5cIF1cW:w MoLVNlM{PDF3NEG=
JEKO-1 M1LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzhOWdYOTBizszN NFvxN3Y4OiCq NX3zU2o{UW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKHOuaXfoeIx6 NVrkUpVGOjN|NEG1OFE>
JEKO-1 NGS4WIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXFOUDPxE1? NWjrNG9TPzJiaB?= MUDkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz NX7sVXJCOjN4N{[yNlA>
MAVER-1 NYfncVRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfrVpE2KM7:TR?= M{TEeVczKGh? NHnnZo5ld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ MXuyN|Y4PjJ{MB?=
MINO MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLOUDPxE1? MXS3NkBp M{fNZYRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> Mn7JNlM3PzZ{MkC=
SP53 NYnleohKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlEh|ryP MnewO|IhcA>? NGf2VYlld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ NE\wU4kzOzZ5NkKyNC=>
HH NILHXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L4RlExKM7:TR?= NF33cow4OiCq Moq5SG1UVw>? MnriTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NWXpfYQ1OjJ6MEG5OVk>
Myla NIfXTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2b4lIOTBizszN MXG3NkBp Mn3tSG1UVw>? MWXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| MUKyNlgxOTl3OR?=
SR786 M1;VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrUeHAyOCEQvF2= M{TrfVczKGh? MoHCSG1UVw>? NUX4WmlW\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NHTUcpUzOjhyMUm1PS=>
HuT78 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS2VG5DOTBizszN NGnqbHk4OiCq M2LDdGROW09? M3jPW4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MVKyNlgxOTl3OR?=
MJ M1W5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXCNVAh|ryP NGTFXWk4OiCq M2Gzc2ROW09? MYXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NFTJTmQzOjhyMUm1PS=>
DERL7 NInFXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj3c4kyOCEQvF2= M{PLd|czKGh? M3O4bGROW09? NFq2eXNld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz MUmyNlgxOTl3OR?=
L1236 NIrINnFHfW6ldHnvckBCe3OjeR?= MmLwNVAh|ryP MmrINkBp NEP5[JJKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= NWXININyOjJ{MUC4O|c>
L428 NUD6Ro15TnWwY4Tpc44hSXO|YYm= M4TWO|ExKM7:TR?= NELJZWkzKGh? MkPHTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w MmSyNlIzOTB6N{e=
L591 MVPGeY5kfGmxbjDBd5NigQ>? NWHnRVBLOTBizszN M3zWeVIhcA>? MXXJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? M3LSeVIzOjFyOEe3
KMH-2 MkHISpVv[3Srb36gRZN{[Xl? NW\2VoNXOTBizszN MoO0NkBp Mn3xTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w NWPLSmp1OjJ{MUC4O|c>
L1236 MYDGeY5kfGmxbjDBd5NigQ>? NVjCTGhUPSEQvF2= M1nwTVI1KGh? NFvINJRDdG:la4Ogd4VkemW2aX;uJI9nKHSqZTDDR2w2 MoWzNlIzOTB6N{e=
L591 Mor0SpVv[3Srb36gRZN{[Xl? Mo\vOUDPxE1? NYLnR|RpOjRiaB?= NGXmXIVDdG:la4Ogd4VkemW2aX;uJI9nKHSqZTDDR2w2 M4W4OVIzOjFyOEe3
L1236 M3SxUWFxd3C2b4Ppd{BCe3OjeR?= NIrWc3c2KM7:TR?= MkXENlQhcA>? Mn\LTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? M1GwOlIzOjFyOEe3
L591 M{n4OGFxd3C2b4Ppd{BCe3OjeR?= NHGwfoQ2KM7:TR?= NX;6fmZNOjRiaB?= Mk\2TY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? M3LzTlIzOjFyOEe3
U-87MG NUfRcmJ3TnWwY4Tpc44hSXO|YYm= MnjWNVAxKG6P MknyNlQhcA>? M3jxO2ROW09? M2O3OmlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v Mlv0NlIxPzl4MEm=
SW1783 M3rafWZ2dmO2aX;uJGF{e2G7 NF7POYkyODBibl2= MXKyOEBp NV;1SFRCTE2VTx?= M2jXPGlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v NWLPSlN6OjJyN{m2NFk>
U-87MG MULGeY5kfGmxbjDBd5NigQ>? MoT1OUDPxE1? MVqyOEBp MXnEUXNQ MnfQTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> MWGyNlA4QTZyOR?=
SW1783 MlvKSpVv[3Srb36gRZN{[Xl? NYi4[FZxPSEQvF2= M{O4TlI1KGh? NGe0NWFFVVOR MlzvTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> MmTXNlIxPzl4MEm=
U-373MG NYS4cZBSTnWwY4Tpc44hSXO|YYm= Ml\OOUDPxE1? M1fKNFI1KGh? MkLKSG1UVw>? NWPxPWJEUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? M4C0VFIzODd7NkC5
SK-MG3 NEXPN5RHfW6ldHnvckBCe3OjeR?= MYO1JO69VQ>? M3XRNFI1KGh? NYPXbW05TE2VTx?= MX\Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=> MoLGNlIxPzl4MEm=
SU-DHL-5 MXTGeY5kfGmxbjDBd5NigQ>? MWmxJO69VQ>? NG\r[WgzPCCq NYrre|VpTE2VTx?= NWfRNmllUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MkjBNlA6PTl4ME[=
WSU-NHL NXXPTm5mTnWwY4Tpc44hSXO|YYm= M363NVEh|ryP M4jyUlI1KGh? MWTEUXNQ Mmi0TY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? MVSyNFk2QTZyNh?=
CCRF-SB MlfpSpVv[3Srb36gRZN{[Xl? MnXGNUDPxE1? MlfrNlQhcA>? NECwfGxFVVOR NY\tWFBjUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= NGOxfGkzODl3OU[wOi=>
INA-6 MVHGeY5kfGmxbjDBd5NigQ>? NFrIb2I2KM7:TR?= Ml3hOkBp MlTLTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> NGHjNIgzODVyNUG1PC=>
LB M1zGbmZ2dmO2aX;uJGF{e2G7 M{HFTlUh|ryP Mnz1OkBp Mk\vTY5pcWKrdHnvckBw\iCSSUTLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> NF3CfnMzODVyNUG1PC=>

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K实验:

用全CLL和正常B细胞溶解物进行PI3K实验。 进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer(包含 ATP)的混合物中,在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合,反应终止,在室温下温育1小时。混合物转移到PI3K ELISA板上,再温育1小时。 冲洗反应板,然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液 ,反应5分钟,加入H2SO4 终止反应。在450纳米处读数。
细胞实验:[2]
+ 展开
  • Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48小时
  • Method: 进行MTT实验测定细胞毒性。1×105个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时,然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力,分析数据。每个样本至少计数104个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。 基质共培养 在75cm2培养瓶 (80%-100% 融合率) 培养24 小时,然后加入CLL细胞。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.42
化学式

C22H18FN7O

CAS号 870281-82-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03639324 Not yet recruiting Chronic Lymphocytic Leukemia|CLL|Relapsed CLL|Refractory Chronic Lymphocytic Leukemia|Relapsed Chronic Lymphocytic Leukemia Virginia Commonwealth University January 31 2019 Phase 1
NCT03545035 Not yet recruiting Chronic Lymphocytic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto|ERIC Group December 2018 --
NCT03582098 Recruiting Chronic Lymphocytic Leukaemia Gilead Sciences September 12 2018 --
NCT03742323 Recruiting Acute Lymphoblastic Leukemia PETHEMA Foundation July 1 2018 Phase 1|Phase 2
NCT03151057 Recruiting B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Gilead Sciences July 31 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)供应商 | 采购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)价格 | Idelalisib (CAL-101, GS-1101)生产 | 订购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID